Cell therapeutics company MaxCyte Inc (Nasdaq: MXCT) (LSE: MXCT) and Oribiotech Ltd, a provider of cell and gene therapy (CGT) manufacturing technology, announced on Wednesday that the two companies have entered a strategic collaboration to enhance the manufacturing efficiency, scalability and adoption of autologous cell therapies by integrating their respective ExPERT and IRO platforms.

The partnership evaluates the combined performance of MaxCyte's Flow Electroporation technology and Ori's automated IRO platform, focusing on CRISPR knock-in of CD19 CAR in primary T cells. Initial testing aims to demonstrate improvements in yield and reductions in manufacturing timelines compared to traditional cell expansion processes.

MaxCyte's ExPERT platform offers clinical-scale, flexible transfection capabilities, while Ori's IRO system delivers automation through advanced fluid handling and sterile connection technologies. Together, the platforms enable streamlined, high-throughput production of gene-edited T cells, supporting faster and more efficient transition from research to clinical and commercial stages.

This collaboration underscores both companies' commitment to accelerating access to next-generation cell therapies through integrated, high-performance manufacturing solutions.